AlzChem Group AG

XTRA:ACT 株式レポート

時価総額：€1.3b

AlzChem Group マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Andreas Niedermaier

最高経営責任者

€3.2m

報酬総額

CEO給与比率10.98%
CEO在任期間14.1yrs
CEOの所有権n/a
経営陣の平均在職期間9.8yrs
取締役会の平均在任期間12.5yrs

経営陣の近況

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

May 05
AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't

Nov 24
AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't

AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 13
AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate

Is AlzChem Group (ETR:ACT) Using Too Much Debt?

Sep 13
Is AlzChem Group (ETR:ACT) Using Too Much Debt?

Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Aug 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 02
AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 22
AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)

Jun 02
Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)

A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)

May 19
A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)

What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You

May 05
What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

May 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?

May 01
Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Mar 28
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case

Mar 18
With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case

AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 05
AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Mar 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80

Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)

Feb 19
Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)
User avatar

Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position

Strategic expansion in production capacities and collaboration with the U.S. Department of Defense could bolster long-term revenue and market diversification.

AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point

Nov 14
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point

AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story

Oct 27
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story

When Should You Buy AlzChem Group AG (ETR:ACT)?

Oct 18
When Should You Buy AlzChem Group AG (ETR:ACT)?

AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 26
AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Is AlzChem Group (ETR:ACT) A Risky Investment?

Apr 11
Is AlzChem Group (ETR:ACT) A Risky Investment?

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Mar 07
The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Nov 01
Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

Oct 12
Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

May 06
AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

May 05
AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

Apr 05
AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

Mar 04
AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

CEO報酬分析

AlzChem Group の収益と比較して、Andreas Niedermaier の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2025n/an/a

€62m

Jun 30 2025n/an/a

€58m

Mar 31 2025n/an/a

€56m

Dec 31 2024€3m€350k

€54m

Sep 30 2024n/an/a

€50m

Jun 30 2024n/an/a

€46m

Mar 31 2024n/an/a

€39m

Dec 31 2023€2m€315k

€35m

Sep 30 2023n/an/a

€30m

Jun 30 2023n/an/a

€28m

Mar 31 2023n/an/a

€30m

Dec 31 2022€818k€315k

€30m

Sep 30 2022n/an/a

€29m

Jun 30 2022n/an/a

€28m

Mar 31 2022n/an/a

€27m

Dec 31 2021€890k€300k

€28m

Sep 30 2021n/an/a

€27m

Jun 30 2021n/an/a

€26m

Mar 31 2021n/an/a

€23m

Dec 31 2020€786k€300k

€20m

Sep 30 2020n/an/a

€16m

Jun 30 2020n/an/a

€17m

Mar 31 2020n/an/a

€17m

Dec 31 2019€915k€260k

€18m

報酬と市場: Andreasの 総報酬 ($USD 3.67M ) は、 German市場 ($USD 1.66M ) の同規模の企業の平均を上回っています。

報酬と収益: Andreasの報酬は過去 1 年間で 20% 以上増加しました。

CEO

Andreas Niedermaier (56 yo)

14.1yrs
在職期間
€3,188,000
報酬

Mr. Andreas Niedermaier has been Chairman of Executive Board & Chief Executive Officer at AlzChem Group AG since July 01, 2019 and has been its Member of Management Board since October 20, 2011. He served...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Andreas Niedermaier
CEO & Chairman of Executive Board14.1yrs€3.19mデータなし
Andreas Losler
CFO & Member of Management Board1.8yrs€1.45mデータなし
Klaus Englmaier
Member of Executive Board & COO9.8yrs€1.90mデータなし
Georg Weichselbaumer
Chief Sales Officer & Member of Executive Board13.6yrs€1.81mデータなし
Martina Spitzer
Chief Sales Officer & Member of Management Boardless than a yearデータなしデータなし
9.8yrs
平均在職期間
56yo
平均年齢

経験豊富な経営陣: ACTの経営陣は経験豊富で経験豊富です（平均在職期間は9.8年）。

取締役

名称ポジション在職期間報酬所有権
Markus Zöllner
Chairman of the Supervisory Board16.1yrs€42.00kデータなし
Martina Heigl-Murauer
Independent Member of the Supervisory Board9yrs€24.00kデータなし
Caspar von Schnurbein
Deputy Chairman of the Supervisory Board9yrs€32.00kデータなし
Steve Röper
Member of the Supervisory Board16.1yrs€22.00kデータなし
12.5yrs
平均在職期間
54.5yo
平均年齢

経験豊富なボード: ACTの 取締役会 は経験豊富で 経験豊富 です ( 12.5年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/11/24 09:01
終値2025/11/21 00:00
収益2025/09/30
年間収益2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

AlzChem Group AG 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6

アナリスト機関
Volker BosseBaader Helvea Equity Research
Konstantin WiechertBaader Helvea Equity Research
Gerhard OrgonasBerenberg